RNA Atrium Therapeutics, Inc.
HealthcareAs of 2026-05-25
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.96
P/S
10.93
EV/EBITDA
0.63
DCF Value
$-17.89
FCF Yield
-23.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
99.3%
Operating Margin
-318.7%
Net Margin
-315.7%
ROE
-29.7%
ROA
-22.1%
ROIC
-23.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 null | $19.6M | $-16.6M | $— |
| Q4 null | $859.0K | $-48.1M | $— |
| FY null | $18.6M | $-76.7M | $— |
| Q3 2025 | $12.5M | $-174.4M | $-1.27 |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$25.00
Target (Median)
$25.00
Target Range
$25.00 - $25.00
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.00
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.